Jentadueto® (linagliptin/metformin) Tablets for Type 2 Diabetes

What Jentadueto® Is and How It Works

Jentadueto combines two diabetes medicines: linagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, and metformin hydrochloride, a biguanide. It is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. The tablets are taken by mouth and are typically dosed twice daily with meals.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. Our vetted partners supply authentic brand medications across a broad selection at value‑focused pricing.

Strengths include linagliptin 2.5 mg paired with metformin 500 mg, 850 mg, or 1000 mg. These immediate‑release tablets differ from Jentadueto XR, which uses extended‑release metformin. Your healthcare provider selects a dose based on prior therapy, A1C goals, renal function, and tolerability.

How it works: linagliptin increases incretin activity, which raises insulin secretion and lowers glucagon when glucose is elevated. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Together, they address fasting and post‑meal glucose. For typical jentadueto 2.5 1000 mg uses, the goal is steady A1C reduction without weight gain and with a low risk of hypoglycemia when not used with insulin or a sulfonylurea. For detailed background, see our article Jentadueto Uses Dosage.

Dosage and Usage

• Usual adult dosing: one tablet twice daily with meals. Tablets combine linagliptin 2.5 mg with metformin 500 mg, 850 mg, or 1000 mg.
• Initiation: if not on metformin, a common start is 2.5 mg/500 mg twice daily; dose may increase in 500 mg metformin steps based on response and tolerability.
• Switching from separate tablets: match the nearest total daily metformin dose and linagliptin 5 mg/day (as 2.5 mg twice daily).
• Do not crush or split tablets. Swallow whole with water and take with food to reduce stomach upset.
• Missed dose: take when remembered unless it is near the next dose. Do not double up.
• Jentadueto XR is a different formulation taken once daily; do not interchange tablet types without medical guidance.
• Renal and hepatic considerations affect metformin use. Clinicians assess kidney function and other risks before and during treatment.

Storage and Travel

• Store tablets at 20–25°C (68–77°F). Excursions 15–30°C (59–86°F) are acceptable.
• Keep in the original, tightly closed container. Protect from moisture.
• Do not store in a bathroom or near sinks. Avoid excessive heat.
• For travel, keep medicine in carry‑on luggage with a copy of your prescription.
• If a tablet looks damaged or discolored, consult a pharmacist before use.

Benefits and Savings

Combining a DPP‑4 inhibitor with metformin can produce meaningful A1C reductions and improve both fasting and postprandial glucose. Jentadueto is generally weight‑neutral. It offers convenient co‑formulation to reduce pill burden compared with taking linagliptin and metformin separately. The risk of hypoglycemia is low when not used with insulin or a sulfonylurea.

Flexible strengths allow matching the metformin component (e.g., linagliptin 2.5 metformin 1000) while keeping linagliptin at its once‑daily total of 5 mg. Many customers save 60–80% vs typical U.S. prices. See our promotions page for current offers, including any jentadueto coupon if available.

If you are comparing jentadueto cost between strengths such as 2.5/500 mg, 2.5/850 mg, or 2.5/1000 mg, review pricing by quantity to match your prescribed dosing schedule.

Side Effects and Safety

• Common: diarrhea, nausea, abdominal discomfort, gas, decreased appetite, headache, and nasopharyngitis.
• Less common: cough, back pain, dizziness, metallic taste, or fatigue.
• GI effects often appear at initiation or dose increases and may lessen over time.
• Vitamin B12 levels may decline with long‑term metformin; clinicians monitor as needed.
• Hypoglycemia risk increases when combined with insulin or a sulfonylurea.

Serious risks are uncommon but include lactic acidosis with metformin, pancreatitis with DPP‑4 inhibitors, severe allergic reactions (angioedema, anaphylaxis), bullous pemphigoid, and severe joint pain. Seek urgent care for symptoms such as severe abdominal pain, rapid breathing, unusual sleepiness, swelling of the face or throat, or blistering skin. Jentadueto is not for type 1 diabetes or diabetic ketoacidosis. For more details, read Jentadueto Side Effects.

Onset Time

Glycemic improvements may begin within the first 1–2 weeks as metformin starts lowering hepatic glucose output and linagliptin blunts post‑meal excursions. A1C reductions continue as dosing stabilizes, with most of the effect seen by 8–12 weeks. Gastrointestinal tolerability often improves after the first weeks, especially when doses are taken with meals. Weight effects are typically neutral.

Compare With Alternatives

Other options for type 2 diabetes target different pathways and dosing preferences. Rybelsus® is an oral GLP‑1 receptor agonist (semaglutide) taken once daily on an empty stomach. It can provide larger A1C and weight reductions but requires specific dosing instructions and may cause more gastrointestinal effects.

Trulicity® is a once‑weekly injectable GLP‑1 receptor agonist (dulaglutide). It suits those preferring a weekly injection over daily tablets and often leads to meaningful A1C and weight changes. Mounjaro® (tirzepatide) is a once‑weekly GIP/GLP‑1 agonist that can deliver robust glycemic and weight effects. Choice depends on clinical goals, tolerance, and whether oral or injectable therapy fits best.

Jentadueto XR contains the same linagliptin dose options paired with extended‑release metformin for once‑daily administration. Some patients may prefer the XR profile for gastrointestinal comfort or convenience. Your prescriber determines whether immediate‑release or XR is more suitable.

Combination Therapy

• With SGLT2 inhibitors (e.g., empagliflozin): complementary mechanisms address fasting, post‑meal, and renal glucose excretion.
• With insulin: background insulin doses may require reduction to lower hypoglycemia risk as control improves.
• With sulfonylureas: dose adjustments can reduce low blood sugar risk.
• With statins, antihypertensives, and aspirin (as indicated): supports comprehensive cardiovascular risk management in type 2 diabetes.
• Do not combine with other DPP‑4 inhibitors. Avoid duplicate metformin products.

Patient Suitability and Cost‑Saving Tips

Jentadueto is intended for adults with type 2 diabetes needing additional control beyond lifestyle measures. It is not indicated for type 1 diabetes or for treating ketoacidosis. Suitability depends on kidney function, liver status, alcohol intake, and history of pancreatitis or lactic acidosis risk. Clinicians assess drug interactions and individualized A1C targets.

Cost‑saving ideas: consider a multi‑month supply if appropriate, compare tablet strengths to align with your prescribed metformin dose, and select the package size that matches your dosing schedule (for example, jentadueto 2.5 1000 mg 60 tablets for twice‑daily use). Set simple reorder reminders so you do not run out between visits. If evaluating jentadueto xr price vs immediate‑release, weigh dosing convenience against your prescriber’s guidance.

Authoritative Sources

Jentadueto Prescribing Information (Boehringer Ingelheim/Lilly)

Health Canada Drug Product Database – Jentadueto entry

FDA/Medication Guide via DailyMed – Jentadueto

Order Jentadueto® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This material is educational and does not replace advice from your healthcare professional. Always follow your prescriber’s instructions and the medication guide that comes with your prescription.